X-ZELL shortlisted for 2019 HealthInvestor Asia Award
Singapore, April 2019 – Rare cell detection specialist, X-ZELL, has been shortlisted as a Finalist for the 2019 HealthInvestor Asia Awards.
According to HealthInvestor Asia, X-ZELL has been nominated in the “Diagnostics Deal of the Year” category following the signing of a landmark collaboration agreement with Singapore’s Diagnostics Development (DxD) Hub designed to fast-track the commercialisation of next generation cancer screening technology.
Also nominated for the Award are global investment company, Actis, and healthcare powerhouse, GE Healthcare.
Established in 2018, the HealthInvestor Asia Awards promote excellence and recognise innovation in the private healthcare industry and will be presented on 16 May 2019 at the Marina Bay Sands Convention Centre.
Tickets can be ordered online now.